OCT1 (SLC22A1) R61C polymorphism and response to imatinib treatment in chronic myeloid leukemia patients.

Suppr

超能文献

作者信息

Zach Otto, Krieger Otto, Foedermayr Mathilde, Zellhofer Barbara, Lutz Dieter

出版信息

Leuk Lymphoma. 2008 Nov;49(11):2222-3. doi: 10.1080/10428190802322893.

DOI:10.1080/10428190802322893

PMID:19021069

Abstract

摘要

相似文献

OCT1 (SLC22A1) R61C polymorphism and response to imatinib treatment in chronic myeloid leukemia patients.

Leuk Lymphoma. 2008 Nov;49(11):2222-3. doi: 10.1080/10428190802322893.

Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.采用多个候选基因的药物遗传学方法预测慢性髓性白血病对伊马替尼治疗的反应和耐药性的临床相关性。

Clin Cancer Res. 2009 Jul 15;15(14):4750-8. doi: 10.1158/1078-0432.CCR-09-0145. Epub 2009 Jul 7.

Thrombocytopenia induced by imatinib mesylate (Glivec) in patients with chronic myelogenous leukemia: is 400 mg daily of imatinib mesylate an optimal starting dose for Japanese patients?

Int J Hematol. 2003 Jan;77(1):93-5. doi: 10.1007/BF02982610.

Imatinib-induced aplastic anemia in a patient with chronic myeloid leukemia.

Leuk Lymphoma. 2012 Nov;53(11):2310-1. doi: 10.3109/10428194.2012.680452. Epub 2012 Apr 30.

Multiple skin lesions caused by imatinib mesylate treatment of chronic myeloid leukemia.甲磺酸伊马替尼治疗慢性髓性白血病引起的多发性皮肤病变。

Pol Arch Med Wewn. 2013;123(5):251-2.

Trachyonychia in a patient with chronic myeloid leukaemia after imatinib mesylate.甲磺酸伊马替尼治疗后慢性髓性白血病患者出现的糙甲症

Hong Kong Med J. 2014 Oct;20(5):464.e2. doi: 10.12809/hkmj134084.

Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.多药转运体基因 ABCB1 和 ABCG2 的基因型和单倍型与慢性髓性白血病患者甲磺酸伊马替尼临床反应的相关性。

Biomed Pharmacother. 2014 Apr;68(3):343-9. doi: 10.1016/j.biopha.2014.01.009. Epub 2014 Feb 7.

Unusual extramedullary relapses under imatinib mesylate treatment in chronic myeloid leukemia.慢性髓性白血病患者在甲磺酸伊马替尼治疗下出现的不寻常髓外复发

Am J Hematol. 2005 May;79(1):79-80. doi: 10.1002/ajh.20274.

Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis.甲磺酸伊马替尼诱导的慢性髓性白血病肝毒性表现为类似急性病毒性肝炎的局灶性坏死。

Leukemia. 2002 Oct;16(10):2160-1. doi: 10.1038/sj.leu.2402702.

Spontaneous reversion from blast to chronic phase after withdrawal of imatinib mesylate in a patient with chronic myelogenous leukemia.一名慢性粒细胞白血病患者在停用甲磺酸伊马替尼后从急变期自发逆转至慢性期。

Leuk Lymphoma. 2002 Dec;43(12):2413-5. doi: 10.1080/1042819021000040152.

引用本文的文献

Mitochondria-targeted metformin (mitomet) inhibits lung cancer in cellular models and in mice by enhancing the generation of reactive oxygen species.线粒体靶向二甲双胍（mitomet）通过增强活性氧的生成来抑制细胞模型和小鼠中的肺癌。

Mol Carcinog. 2023 Nov;62(11):1619-1629. doi: 10.1002/mc.23603. Epub 2023 Jul 4.

The Role of Organic Cation Transporters in the Pharmacokinetics, Pharmacodynamics and Drug-Drug Interactions of Tyrosine Kinase Inhibitors.有机阳离子转运体在酪氨酸激酶抑制剂的药代动力学、药效学和药物相互作用中的作用。

Int J Mol Sci. 2023 Jan 20;24(3):2101. doi: 10.3390/ijms24032101.

Role of OCT1 in hepatocellular carcinoma.有机阳离子转运体1在肝细胞癌中的作用。

Onco Targets Ther. 2019 Jul 25;12:6013-6022. doi: 10.2147/OTT.S212088. eCollection 2019.

Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.酪氨酸激酶抑制剂时代的慢性髓性白血病：分子靶向治疗的不断演变模式

Mol Diagn Ther. 2016 Aug;20(4):315-33. doi: 10.1007/s40291-016-0208-1.

Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug-drug interactions.溶质载体家族22成员1（SLC22A1）多态性变体在药物处置、治疗反应及药物相互作用中的作用

Pharmacogenomics J. 2015 Dec;15(6):473-87. doi: 10.1038/tpj.2015.78. Epub 2015 Nov 3.

OCT1 and imatinib transport in CML: is it clinically relevant?OCT1 和伊马替尼在 CML 中的转运：这在临床上有意义吗？

Leukemia. 2015 Oct;29(10):1960-9. doi: 10.1038/leu.2015.170. Epub 2015 Jul 9.

Contribution of tumoral and host solute carriers to clinical drug response.肿瘤和宿主溶质载体对临床药物反应的贡献。

Drug Resist Updat. 2012 Feb-Apr;15(1-2):5-20. doi: 10.1016/j.drup.2012.01.009. Epub 2012 Mar 28.

Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial.酪氨酸激酶抑制剂优化与选择性试验中伊马替尼的血浆暴露及其与临床反应的相关性。

Haematologica. 2012 May;97(5):731-8. doi: 10.3324/haematol.2011.045666. Epub 2012 Feb 7.

Differences in the substrate binding regions of renal organic anion transporters 1 (OAT1) and 3 (OAT3).肾脏有机阴离子转运体 1（OAT1）和 3（OAT3）的底物结合区域的差异。

Am J Physiol Renal Physiol. 2011 Aug;301(2):F378-86. doi: 10.1152/ajprenal.00735.2010. Epub 2011 May 4.

Association of SLCO1B3 polymorphism with intracellular accumulation of imatinib in leukocytes in patients with chronic myeloid leukemia.SLCO1B3 多态性与慢性髓性白血病患者白细胞中伊马替尼的细胞内蓄积的关系。

Biol Pharm Bull. 2011;34(1):114-9. doi: 10.1248/bpb.34.114.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验